Sanofi against Novo Nordisk: postponed judgment in the dispute over drug ads
Karlsruhe - Can pharmaceutical companies advertise allegedly positive side effects of a drug to physicians? The industry expected for Thursday with a groundbreaking for the pharmaceutical industry judgment of the Bundesgerichtshof (BGH) . That the verdict has now postponed to February.
Had sued the pharmaceutical company Sanofi-Aventis. Competing against Novo Nordisk On a leaflet for doctors reported Novo Nordisk, her diabetes means leads to lower weight gain than the Sanofi-preparation.Sanofi-Aventis holds the flyer was misleading. Novo Nordisk relies on his advertisement on a study. The results of this were not enough scientifically backed, argued Sanofi-Aventis.
According to the study, patients should have increased when taking Levemir by Novo Nordisk for 52 weeks only 2.25 kg and 1.65 kg less so than in the Sanofi-drug Lantus with 3.9 kilograms. For diabetics, this is an important point that many of them suffer from the fact that increase insulin preparations may be the body weight.
The lawsuit filed by Sanofi-Aventis was in the lower courts without success. The Berlin Court of Appeal saw no antitrust violation. The results of the study, which was based on the advertising claims were, in the "technical information" contained that had been examined in the authorization procedure for the drug. Therefore be assumed that the advertised weight advantage is consistent with the scientific uncertainty as. This presumption is Sanofi-Aventis does not refute was the Court of Appeal. The Supreme Court will be ruling on 6 now February proclaim.
According to the study, patients should have increased when taking Levemir by Novo Nordisk for 52 weeks only 2.25 kg and 1.65 kg less so than in the Sanofi-drug Lantus with 3.9 kilograms. For diabetics, this is an important point that many of them suffer from the fact that increase insulin preparations may be the body weight.
The lawsuit filed by Sanofi-Aventis was in the lower courts without success. The Berlin Court of Appeal saw no antitrust violation. The results of the study, which was based on the advertising claims were, in the "technical information" contained that had been examined in the authorization procedure for the drug. Therefore be assumed that the advertised weight advantage is consistent with the scientific uncertainty as. This presumption is Sanofi-Aventis does not refute was the Court of Appeal. The Supreme Court will be ruling on 6 now February proclaim.
jme / nik
http://baby.zuxio.com/
Tidak ada komentar:
Posting Komentar